TR201910726T4 - Arginaz inhibitörleri ve kullanım yöntemleri. - Google Patents

Arginaz inhibitörleri ve kullanım yöntemleri. Download PDF

Info

Publication number
TR201910726T4
TR201910726T4 TR2019/10726T TR201910726T TR201910726T4 TR 201910726 T4 TR201910726 T4 TR 201910726T4 TR 2019/10726 T TR2019/10726 T TR 2019/10726T TR 201910726 T TR201910726 T TR 201910726T TR 201910726 T4 TR201910726 T4 TR 201910726T4
Authority
TR
Turkey
Prior art keywords
arginase
usage methods
arginase inhibitors
formula
methods
Prior art date
Application number
TR2019/10726T
Other languages
English (en)
Inventor
W Christianson David
Edward Tomczuk Bruce
Scott Pottorf Richard
Vargha Colasanti Andrew
Lee Olson Gary
Original Assignee
Astrazeneca Uk Ltd
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd, Univ Pennsylvania filed Critical Astrazeneca Uk Ltd
Publication of TR201910726T4 publication Critical patent/TR201910726T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)

Abstract

Mevcut buluş, Formül IA veya Formül IB arginaz inhibitör bileşikleri: veya farmasötik olarak kabul edilebilir bir tuzu, bu bileşikler içeren mevcut bileşimler ve arginazın yukarı regülasyonu, anormal olarak yüksek arginaz etkinliği veya anormal şekilde düşük nitrik oksit sentaz etkinliği ile karakterize olan durumların tedavisi ve teşhisi için kullanım yöntemlerine yöneliktir.
TR2019/10726T 2009-01-26 2010-01-26 Arginaz inhibitörleri ve kullanım yöntemleri. TR201910726T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14727009P 2009-01-26 2009-01-26

Publications (1)

Publication Number Publication Date
TR201910726T4 true TR201910726T4 (tr) 2019-08-21

Family

ID=42354317

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/10726T TR201910726T4 (tr) 2009-01-26 2010-01-26 Arginaz inhibitörleri ve kullanım yöntemleri.

Country Status (16)

Country Link
US (4) US20100189644A1 (tr)
EP (1) EP2389352B1 (tr)
JP (2) JP2012515799A (tr)
CA (1) CA2749853C (tr)
CY (1) CY1121815T1 (tr)
DK (1) DK2389352T3 (tr)
ES (1) ES2729474T3 (tr)
HR (1) HRP20191433T1 (tr)
HU (1) HUE046932T2 (tr)
LT (1) LT2389352T (tr)
PL (1) PL2389352T3 (tr)
PT (1) PT2389352T (tr)
RS (1) RS58965B1 (tr)
SI (1) SI2389352T1 (tr)
TR (1) TR201910726T4 (tr)
WO (1) WO2010085797A2 (tr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX348422B (es) * 2010-04-22 2017-06-12 Mars Inc Inhibidores de arginasa y sus aplicaciones terapeuticas.
SI2632927T1 (sl) * 2010-10-26 2016-08-31 Mars, Incorporated Boronati kot inhibitorji arginaze
US8894970B2 (en) * 2010-12-31 2014-11-25 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
WO2013056163A1 (en) * 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
JP5993459B2 (ja) * 2011-10-19 2016-09-14 マーズ インコーポレイテッド アルギナーゼ阻害剤およびそれらの治療用途
US10299377B2 (en) 2011-12-22 2019-05-21 Fujifilm Corporation Conductive sheet and touch panel
IN2014DN09678A (tr) 2012-04-18 2015-07-31 Mars Inc
KR102146673B1 (ko) * 2012-12-04 2020-08-21 주식회사 아리바이오 포스포디에스테라제 타입 ５ 저해제를 포함하는 신경세포의 아폽토시스 억제용 조성물
AU2015249374A1 (en) 2014-04-24 2016-12-01 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
EP3313410A4 (en) * 2015-06-23 2019-01-02 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
EP3359150A4 (en) * 2015-10-05 2019-11-06 Calithera Biosciences, Inc. COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGICAL AGENTS
LT3368541T (lt) 2015-10-30 2020-09-25 Calithera Biosciences, Inc. Kompozicijos ir būdai, skirti arginazės aktyvumo inhibavimui
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
JP6581308B2 (ja) * 2016-10-17 2019-09-25 一般社団法人 金沢大整形 癌治療剤
US11291674B2 (en) 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
SI3559009T1 (sl) 2016-12-22 2021-08-31 Calithera Biosciences, Inc. Sestavki in postopki za zaviranje arginazne dejavnosti
PE20200339A1 (es) 2017-05-12 2020-02-14 Calithera Biosciences Inc Metodo para preparar (3r, 4s)-3-acetamido-4-alil-n-(terc-butil)pirrolidina-3-carboxamida
IL276813B2 (en) 2018-03-05 2024-09-01 Arcus Biosciences Inc History of 4-substituted 5-amino-octahydrocyclopenta[c]pyrrole-5-carboxylic acid, their pharmaceutical combinations and their use for the treatment of diseases
TWI723366B (zh) 2018-03-29 2021-04-01 波蘭商昂科艾倫迪治療法股份公司 二肽哌啶衍生物
RU2695333C1 (ru) * 2018-09-24 2019-07-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемически-реперфузионных повреждений почек ингибитором аргиназы II в эксперименте
RU2696580C1 (ru) * 2018-09-25 2019-08-05 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики нарушений функций почек ингибитором аргиназы II в эксперименте
BR112021015581A2 (pt) * 2019-02-08 2021-10-05 Astrazeneca Ab Inibidores de arginase e seus métodos de uso
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
CN117417292B (zh) * 2023-02-20 2024-07-12 浙江新码生物医药有限公司 一种含有杂芳基的非天然氨基酸及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477391A (en) * 1981-08-14 1984-10-16 Collins James F Amino acid isomers, their production and their medicinal use
WO1999019295A1 (en) * 1997-10-10 1999-04-22 Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
US6784178B2 (en) * 2000-04-12 2004-08-31 Cornell Research Foundation, Inc. Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity
WO2005025620A2 (en) * 2003-08-13 2005-03-24 Pharmacia Corporation Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents
US20100056480A1 (en) * 2006-11-21 2010-03-04 Rijks Univesiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis

Also Published As

Publication number Publication date
SI2389352T1 (sl) 2019-08-30
EP2389352A2 (en) 2011-11-30
CY1121815T1 (el) 2020-07-31
US10118936B2 (en) 2018-11-06
PT2389352T (pt) 2019-08-23
WO2010085797A2 (en) 2010-07-29
RS58965B1 (sr) 2019-08-30
CA2749853C (en) 2018-08-21
HUE046932T2 (hu) 2020-04-28
LT2389352T (lt) 2019-06-10
JP2015205891A (ja) 2015-11-19
US20160194340A1 (en) 2016-07-07
JP6177832B2 (ja) 2017-08-09
DK2389352T3 (da) 2019-07-29
WO2010085797A3 (en) 2010-11-04
AU2010206535A1 (en) 2011-07-28
CA2749853A1 (en) 2010-07-29
US20100189644A1 (en) 2010-07-29
ES2729474T3 (es) 2019-11-04
EP2389352A4 (en) 2013-02-20
US20190127395A1 (en) 2019-05-02
HRP20191433T1 (hr) 2019-11-15
US20200223871A1 (en) 2020-07-16
JP2012515799A (ja) 2012-07-12
EP2389352B1 (en) 2019-05-08
PL2389352T3 (pl) 2019-10-31

Similar Documents

Publication Publication Date Title
TR201910726T4 (tr) Arginaz inhibitörleri ve kullanım yöntemleri.
MA34069B1 (fr) Dérivés de n-(imidazopyrimidin-7-yl)hétéroarylamide et leur utilisation comme inhibiteurs de pde10a)
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
MX336381B (es) Boronatos como inhibidores de arginasa.
TR201909189T4 (tr) C-kit ki̇naz i̇nhi̇bi̇törü bi̇leşi̇kler ve bi̇leşi̇mler
EA201590661A1 (ru) Азахиназолиновые ингибиторы атипичной протеинкиназы c
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
JO3025B1 (ar) الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3
MX2013008212A (es) Derivados de 7-azaindol.
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
UA110943C2 (uk) N-ацилсульфонамідні промотори апоптозу
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA201270646A1 (ru) Ингибиторы глюкозилцерамидсинтазы
EA201490200A1 (ru) 4-(8-метокси-1-((1-метоксипропан-2-ил)-2-(тетрагидро-2-н-пиран-4-ил)-1н-имидазо[4,5-c]хинолин-7-ил)-3,5-диметилизоксазол и его применение в качестве ингибитора бромодомена
EA201500175A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
EA201100879A1 (ru) Производные пиридопиримидина в качестве ингибиторов аутотаксина
CO6531502A2 (es) Aminotriazolopiridinas y su uso como inhibidores de cinasa
UA108711C2 (uk) Сполуки триазолопіридину як інгібітори фосфодіестерази pde10a
MX341531B (es) Derivados de triazol como estimuladores de la guanilato ciclasa soluble gcs.
GEP20227397B (en) Inhibitors of influenza viruses replication
TR201906936T4 (tr) Protein kinaza yönelik inhibitör aktiviteye sahip tiyenopirimidin türevleri.
UA109667C2 (xx) Похідні хіназолін-4(3h)-ону, що використовуються як інгібітори pi3-кінази
EA201190296A1 (ru) Дисахариновая, дифумарово-кислая, ди-1-гидрокси-2-нафтойно-кислая и монобензойно-кислая соли 4-(диметиламино)бутил-2-(4-((2-амино-4-метил-6-(пентиламино)пиримидин-5-ил)метил)фенил)ацетата